Fortrea Appoints Agnieszka Gallagher as General Counsel
Fortrea (Nasdaq: FTRE) announced on November 17, 2025 the appointment of Agnieszka M. Gallagher as general counsel. Gallagher will lead the company’s legal strategy and operations, serve as corporate secretary and chief compliance officer, and join Fortrea’s leadership team.
Gallagher brings more than 25 years of experience across life sciences, biotech, diagnostics, pharmaceutical and medtech sectors, including roles as chief legal officer at Standard Biotools where she was involved in its merger with SomaLogic, and senior legal and compliance positions at Orasure, Alnylam, ViiV Healthcare, GSK Biologics, Sandoz, Medtronic and Pfizer. She succeeds J. Stillman Hanson, who is leaving after a planned transition period.
Fortrea (Nasdaq: FTRE) ha annunciato il 17 novembre 2025 la nomina di Agnieszka M. Gallagher come general counsel. Gallagher guiderà la strategia legale e le operazioni dell'azienda, fungerà da segretario della società e responsabile della conformità, e entrerà a far parte del team dirigente di Fortrea.
Gallagher porta più di 25 anni di esperienza nei settori life sciences, biotech, diagnostica, farmaceutico e medtech, tra cui ruoli di chief legal officer presso Standard Biotools dove ha partecipato alla fusione con SomaLogic, e posizioni di senior legal e compliance in Orasure, Alnylam, ViiV Healthcare, GSK Biologics, Sandoz, Medtronic e Pfizer. Sostituisce J. Stillman Hanson, che lascia l'azienda dopo un periodo di transizione pianificato.
Fortrea (Nasdaq: FTRE) anunció el 17 de noviembre de 2025 el nombramiento de Agnieszka M. Gallagher como asesora general. Gallagher dirigirá la estrategia legal y las operaciones de la empresa, ejercerá como secretaria corporativa y responsable de cumplimiento, y se unirá al equipo de liderazgo de Fortrea.
Gallagher aporta más de 25 años de experiencia en los sectores de ciencias de la vida, biotecnología, diagnóstico, farmacéutico y medtech, incluyendo cargos como directora jurídica en Standard Biotools donde participó en su fusión con SomaLogic, y cargos sénior legales y de cumplimiento en Orasure, Alnylam, ViiV Healthcare, GSK Biologics, Sandoz, Medtronic y Pfizer. Sustituye a J. Stillman Hanson, quien se va tras un periodo de transición planificado.
Fortrea (나스닥: FTRE)는 2025년 11월 17일 Agnieszka M. Gallagher를 일반 법무 담당으로 임명했다고 발표했습니다. Gallagher는 회사의 법무 전략과 운영을 이끌고, 기업 비서 및 컴플라이언스 책임자를 겸하며 Fortrea의 리더십 팀에 합류합니다.
Gallagher는 생명과학, 생명공학, 진단, 제약 및 메드테크 분야에서 25년 이상의 경력을 보유하고 있으며, Standard Biotools에서 최고 법무 책임자로 재직하며 SomaLogic와의 합병에 관여했고, Orasure, Alnylam, ViiV Healthcare, GSK Biologics, Sandoz, Medtronic 및 Pfizer에서 법무 및 컴플라이언스 고위 직책을 역임했습니다. 그녀는 계획된 전환 기간 후 회사를 떠나는 J. Stillman Hanson의 후임으로 임명됩니다.
Fortrea (Nasdaq : FTRE) a annoncé le 17 novembre 2025 la nomination d'Agnieszka M. Gallagher au poste de conseillère générale. Gallagher dirigera la stratégie juridique et les opérations de l'entreprise, assurera les fonctions de secrétaire juridique et de responsable conformité, et rejoindra l'équipe dirigeante de Fortrea.
Gallagher apporte plus de 25 ans d'expérience dans les domaines des sciences de la vie, de la biotechnologie, du diagnostic, du pharmaceutique et du medtech, notamment en tant que directrice juridique chez Standard Biotools où elle a participé à sa fusion avec SomaLogic, ainsi que des postes juridiques et de conformité chez Orasure, Alnylam, ViiV Healthcare, GSK Biologics, Sandoz, Medtronic et Pfizer. Elle succède à J. Stillman Hanson, qui quitte l'entreprise après une période de transition planifiée.
Fortrea (Nasdaq: FTRE) gab am 16. November 2025 die Ernennung von Agnieszka M. Gallagher zur General Counsel bekannt. Gallagher wird die Rechtsstrategie und -organisation des Unternehmens leiten, als Corporate Secretary und Chief Compliance Officer fungieren und dem Führungsteam von Fortrea beitreten.
Gallagher verfügt über mehr als 25 Jahre Erfahrung in den Bereichen Life Sciences, Biotechnologie, Diagnostik, Pharma und Medtech, darunter Positionen als Chief Legal Officer bei Standard Biotools, wo sie an der Fusion mit SomaLogic beteiligt war, sowie Senior Legal- und Compliance-Positionen bei Orasure, Alnylam, ViiV Healthcare, GSK Biologics, Sandoz, Medtronic und Pfizer. Sie tritt die Nachfolge von J. Stillman Hanson an, der nach einer geplanten Übergangsphase das Unternehmen verlässt.
فورتريا (ناسداك: FTRE) أعلنت عن تعيين Agnieszka M. Gallagher كالمستشارة العامة. ستقود Gallagher الاستراتيجية القانونية وعمليات الشركة، وستتولى منصب أمين سر الشركات و رئيس الامتثال، لتنضم إلى فريق القيادة في Fortrea.
تتمتع Gallagher بخبرة تزيد عن 25 عاماً في مجالات علوم الحياة والتكنولوجيا الحيوية والتشخيص والصيدلة والتقنيات الطبية، بما في ذلك مناصبها كـ Chief Legal Officer لدى Standard Biotools حيث شاركت في دمجها مع SomaLogic، فضلاً عن مناصب عليا في القانون والامتثال لدى Orasure وAlnylam وViiV Healthcare وGSK Biologics وSandoz وMedtronic وPfizer. ستحل مكان J. Stillman Hanson الذي سيغادر após فترة انتقال مخطط لها.
- Appointment announced on November 17, 2025
- Gallagher brings >25 years of life‑sciences legal experience
- Held CLO role at Standard Biotools; involved in merger with SomaLogic
- Will serve as corporate secretary and chief compliance officer
- J. Stillman Hanson is leaving after a planned transition period
DURHAM, N.C., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced the appointment of Agnieszka (Aggie) M. Gallagher as general counsel. Gallagher is responsible for the Company’s legal strategy and operations, serving as corporate secretary, chief compliance officer and as a member of Fortrea’s leadership team. She succeeds J. Stillman Hanson, who is leaving the Company after a planned transition period.
“Aggie brings broad and deep executive experience in the life sciences and beyond to Fortrea, with a track record of navigating complexity in global companies,” said Anshul Thakral, CEO of Fortrea. “Aggie is a business leader with proven success in driving commercial opportunities, corporate governance and risk management. She is known for aligning legal strategy with corporate objectives. I’m pleased to welcome her to the global community that is Fortrea. At the same time, I also would like to thank Stillman for his leadership over the past few years as Fortrea was founded and established strong roots. On behalf of the Fortrea Board and the entire Fortrea team, we appreciate all that he has done and wish him every success in his future endeavors.”
Gallagher has more than 25 years of experience in the life sciences, biotechnology, diagnostics, pharmaceutical and medtech sectors. Most recently, she was chief legal officer and corporate secretary at Standard Biotools, Inc., where she played a key role in the completion of its merger with SomaLogic. Previously, Gallagher served as general counsel, chief compliance officer and company secretary at Orasure Technologies, where she oversaw its legal, regulatory affairs and quality assurance functions. She was chief compliance and ethics officer at Alnylam Pharmaceuticals and has served in leadership roles in legal and compliance at ViiV Healthcare, GSK Biologics, Sandoz International, Medtronic and Pfizer. Gallagher began her legal career at White & Case LLP, an international law firm serving companies, governments and financial institutions.
Gallagher holds a Juris Doctor from Rutgers Law School and earned her Bachelor of Arts in Spanish and Political Science from Rutgers College. She is admitted to the bar in New York and New Jersey.
“I’m honored to join Fortrea during such a pivotal moment in its journey,” said Gallagher. “I look forward to collaborating with our global team and our partners as we accelerate the development of innovative treatments. The opportunity to work alongside world-class developers and to uphold the highest standards of governance and compliance is both inspiring and energizing. I am eager to get started.”
About Fortrea
Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team working in about 100 countries is scaled to deliver focused and agile solutions to customers globally. Learn more about how Fortrea is becoming a transformative force from pipeline to patient at Fortrea.com and follow us on LinkedIn and X (formerly Twitter).
Fortrea Contacts:
Tracy Krumme (Investors) – 984-385-6707, Tracy.Krumme@fortrea.com
Sue Zaranek (Media) – 919-943-5422, media@fortrea.com
Kate Dillon (Media) – 646-818-9115, kdillon@prosek.com
FAQ
Who has Fortrea (FTRE) named as general counsel on November 17, 2025?
What roles will Agnieszka Gallagher hold at Fortrea (FTRE)?
What experience does Fortrea's new GC Agnieszka Gallagher have relevant to FTRE?
Who is departing as Fortrea's general counsel and when is the transition?
Does the Fortrea (FTRE) announcement mention Gallagher's role in any major transactions?
What are the immediate governance responsibilities for Fortrea's new GC (FTRE)?
